Exemplifying Interspecies Variation of Liposome Fate by the Effects of Anti-PEG Antibodies

Overview

Journal Acta Pharm Sin B

Publisher Elsevier

Specialty Pharmacology

Date 2024 Dec 12

PMID 39664439

Authors

Ercan Wu

Juan Guan

Yifei Yu

Shiqi Lin

Tianhao Ding

Yuxiu Chu

Feng Pan

Mengyuan Liu

Yang Yang

Zui Zhang

Jian Zhang

Changyou Zhan

Jun Qian

Affiliations

Soon will be listed here.

Abstract

The different fate of liposomes among species has been discovered and mentioned in many studies, but the underlying mechanisms have not been explored. In the present work, we concentrated on the fate of PEGylated liposomes (sLip) in three commonly used species (mice, rats, and dogs). It was exhibited that the accelerated blood clearance (ABC) phenomenon and hypersensitivity in large animals (beagle dogs) were much more significant than that in rodents. We demonstrated that anti-PEG IgM (partially) and complement (mostly) determined the elimination of sLip and linked the distinct interspecies performances with the diverse complement capacity among species. Based on the data from animals and clinical patients, it was revealed that the fate of sLip in large animals was closer to that in humans, for the sufficient complement capacity could expose the potential adverse reactions caused by anti-PEG antibodies. Our results suggested that the distinctive interspecies performances of sLip were highly related to the physiological variabilities among species, which should not be overlooked in the innovation and translation of nanomedicines.

Citing Articles

Emerging strategies against accelerated blood clearance phenomenon of nanocarrier drug delivery systems.

Pan J, Wang Y, Chen Y, Zhang C, Deng H, Lu J J Nanobiotechnology. 2025; 23(1):138.

PMID: 40001108 PMC: 11853785. DOI: 10.1186/s12951-025-03209-0.

References

Tang W, Zhang Z, Li C, Chu Y, Qian J, Ying T . Facile Separation of PEGylated Liposomes Enabled by Anti-PEG scFv. Nano Lett. 2021; 21(23):10107-10113. DOI: 10.1021/acs.nanolett.1c03946. View

Ibrahim M, Shimizu T, Ando H, Ishima Y, Elgarhy O, Sarhan H . Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice. J Control Release. 2023; 354:260-267. DOI: 10.1016/j.jconrel.2023.01.012. View

Day C, Merlino G, Van Dyke T . Preclinical mouse cancer models: a maze of opportunities and challenges. Cell. 2015; 163(1):39-53. PMC: 4583714. DOI: 10.1016/j.cell.2015.08.068. View

Qiu S, Liu Z, Hou L, Li Y, Wang J, Wang H . Complement activation associated with polysorbate 80 in beagle dogs. Int Immunopharmacol. 2012; 15(1):144-9. DOI: 10.1016/j.intimp.2012.10.021. View

Wang W, Huang Z, Li Y, Wang W, Shi J, Fu F . Impact of particle size and pH on protein corona formation of solid lipid nanoparticles: A proof-of-concept study. Acta Pharm Sin B. 2021; 11(4):1030-1046. PMC: 8105779. DOI: 10.1016/j.apsb.2020.10.023. View

Valcourt D, Kapadia C, Scully M, Dang M, Day E . Best Practices for Preclinical In Vivo Testing of Cancer Nanomedicines. Adv Healthc Mater. 2020; 9(12):e2000110. PMC: 7473451. DOI: 10.1002/adhm.202000110. View

Dezsi L, Fulop T, Meszaros T, Szenasi G, Urbanics R, Vazsonyi C . Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses. J Control Release. 2014; 195:2-10. DOI: 10.1016/j.jconrel.2014.08.009. View

Lubich C, Allacher P, de la Rosa M, Bauer A, Prenninger T, Horling F . The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?. Pharm Res. 2016; 33(9):2239-49. DOI: 10.1007/s11095-016-1961-x. View

Ehlinger C, Spear N, Doddareddy R, Shankar G, Schantz A . A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum. J Immunol Methods. 2019; 474:112669. DOI: 10.1016/j.jim.2019.112669. View

10.

Arami H, Patel C, Madsen S, Dickinson P, Davis R, Zeng Y . Nanomedicine for Spontaneous Brain Tumors: A Companion Clinical Trial. ACS Nano. 2019; 13(3):2858-2869. PMC: 6584029. DOI: 10.1021/acsnano.8b04406. View

11.

Filipczak N, Pan J, Yalamarty S, Torchilin V . Recent advancements in liposome technology. Adv Drug Deliv Rev. 2020; 156:4-22. DOI: 10.1016/j.addr.2020.06.022. View

12.

Zhang P, Sun F, Liu S, Jiang S . Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation. J Control Release. 2016; 244(Pt B):184-193. PMC: 5747248. DOI: 10.1016/j.jconrel.2016.06.040. View

13.

Guidolin K, Zheng G . Nanomedicines Lost in Translation. ACS Nano. 2019; 13(12):13620-13626. DOI: 10.1021/acsnano.9b08659. View

14.

Klibanov A, Maruyama K, Torchilin V, Huang L . Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990; 268(1):235-7. DOI: 10.1016/0014-5793(90)81016-h. View

15.

Brodin P, Davis M . Human immune system variation. Nat Rev Immunol. 2016; 17(1):21-29. PMC: 5328245. DOI: 10.1038/nri.2016.125. View

16.

Yang Z, Aderemi O, Zhao Q, Edsall P, Simovic M, Lund B . Early Complement and Fibrinolytic Activation in a Rat Model of Blast-Induced Multi-Organ Damage. Mil Med. 2019; 184(Suppl 1):282-290. DOI: 10.1093/milmed/usy412. View

17.

Chen B, Su Y, Chang C, Burnouf P, Chuang K, Chen C . Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. Anal Chem. 2016; 88(21):10661-10666. DOI: 10.1021/acs.analchem.6b03109. View

18.

Li Y, Wang G, Griffin L, Banda N, Saba L, Groman E . Complement opsonization of nanoparticles: Differences between humans and preclinical species. J Control Release. 2021; 338:548-556. PMC: 8552414. DOI: 10.1016/j.jconrel.2021.08.048. View

19.

Robson A, Dastoor P, Flynn J, Palmer W, Martin A, Smith D . Advantages and Limitations of Current Imaging Techniques for Characterizing Liposome Morphology. Front Pharmacol. 2018; 9:80. PMC: 5808202. DOI: 10.3389/fphar.2018.00080. View

20.

Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique N, Alving C . Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol. 2003; 14(9):1430-7. DOI: 10.1093/annonc/mdg374. View